Tm Bioscience to Supply St. Joseph's Hospital with Tag-It™ Reagents
News Feb 16, 2006
"We selected Tm's Tag-It™ platform because we were impressed by its performance and flexibility. Tm's technology has allowed us to develop an assay testing for numerous CF associated mutations at once in a single well, an extremely time-efficient and cost-effective solution," said John Stone, Director of Laboratory Services at St. Joseph's Hospital.
"Because the platform is open and flexible, we ultimately anticipate providing our patients with a broader menu of important genetic tests using Tm reagents."
"We look forward to working with St. Joseph's Hospital to provide leading edge medical laboratory services for the state of Arizona," said Greg Hines, President and CEO of Tm Bioscience.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.